Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Nov;19(4):156-64.

2011 update of the drug resistance mutations in HIV-1

Victoria A Johnson  1 , Vincent Calvez, Huldrych F Günthard, Roger Paredes, Deenan Pillay, Robert Shafer, Annemarie M Wensing, Douglas D Richman
Affiliations
Review

2011 update of the drug resistance mutations in HIV-1

Victoria A Johnson et al. Top Antivir Med. 2011 Nov.

Abstract

This November 2011 edition of the IAS-USA drug resistance mutations list updates the figures last published in December 2010 (Johnson VA et al, Top HIV Med, 2010;18:156-163).

PubMed Disclaimer

Conflict of interest statement

Financial Disclosures: The authors (listed alphabetically) disclose the following affiliations with commercial organizations that may have interests related to the content of this article (previous 12 months): Dr Calvez has served on advisory boards for Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Janssen Pharmaceutica, Pfizer, Inc, Roche, and ViiV Healthcare. Dr Günthard has served as a consultant or medical advisor for Abbott Laboratories, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novartis AG, and Tibotec Pharmaceuticals; has received unrestricted research grants from Abbott Laboratories, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc, GlaxoSmithKline, Merck Sharp & Dohme Corp, Tibotec Pharmaceuticals, and ViiV Healthcare; and has received travel grants from Abbott Laboratories, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc, GlaxoSmithKline, Merck Sharp & Dohme Corp, Tibotec Pharmaceuticals, and ViiV Healthcare. Dr Johnson has received research support from Abbott Molecular, Roche Molecular Diagnostics, and Siemens Healthcare Diagnostics Inc. Dr Paredes has served as a consultant or medical advisor for Roche Diagnostics and ViiV Healthcare, and has received research grants awarded to IrsiCaixa and Lluita Contra la SIDA Foundations from Merck Sharp & Dohme Corp and ViiV Healthcare. Dr Pillay has no relevant financial affiliations to disclose. Dr Richman has been a consultant to Biota, Bristol-Myers Squibb, CHIMERx, Gen-Probe Inc, Gilead Sciences, Inc, Idenix Pharmaceuticals, Inc, Johnson & Johnson, Merck & Co, Inc, and Monogram Biosciences, Inc; received research grants or contracts from Merck & Co, Inc; and has been a stock options holder of CHIMERx and Idenix Pharmaceuticals, Inc. Dr Shafer has served as a consultant or medical advisor for Celera and Siemens Healthcare and has received grants from F. Hoffmann-La Roche Ltd and Gilead Sciences, Inc. Dr Wensing has served as a consultant or medical advisor for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, and ViiV Healthcare; has received grants from Merck & Co, Inc, and ViiV Healthcare; and has received travel, accommodations, or meeting expenses from Bristol-Myers Squibb, Gilead Sciences, Inc, and Merck & Co, Inc. The IAS–USA has received grants in the past year for selected continuing medical education activities that are pooled (ie, no single company supports any particular effort) from Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Tibotec Therapeutics, Vertex Pharmaceuticals, and ViiV Healthcare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Clark SA, Shulman NS, Bosch RJ, Mellors JW. Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. AIDS. 2006;20:981-984. - PubMed
    1. Picchio G, Vingerhoets J, Parkin N, Azijn H, de Bethune MP. Nucleoside-associated mutations cause hypersusceptibility to etravirine. [Abstract 23.] Antivir Ther. 2008;13(Suppl 3):A25.
    1. Shulman NS, Bosch RJ, Mellors JW, Albrecht MA, Katzenstein DA. Genetic correlates of efavirenz hypersusceptibility. AIDS. 2004;18:1781-1785. - PubMed
    1. Demeter LM, DeGruttola V, Lustgarten S, et al. Association of efavirenz hypersus-ceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin TriSals. 2008;9:11-25. - PMC - PubMed
    1. Haubrich RH, Kemper CA, Hellmann NS, et al. The clinical relevance of nonnucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS. 2002;16:F33-F40. - PubMed

Publication types